Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1993-08-05
2000-08-29
Minnifield, Nita
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
424 92, 4241841, 4241921, 4242031, 530350, 530412, 530413, 530417, 530418, 530422, 435 693, A61K 3904, A61K 3900, C07K 100, C07K 1600
Patent
active
061104698
ABSTRACT:
The invention concerns a hybrid plasmid for the expression of unfused 38 kDa antigen of M. tuberculosis in E. coli, E. coli with the plasmid, an 38 kDa antigen and a protein of about 33 kDa useful for diagnoses.
REFERENCES:
Lazar et al. Mol. Cell biology 8(3):1247-1252, Mar. 1988.
Burgess et al. J. Cell Biology 111:2129-38, Nov. 1990.
Singh et al. Gene 117(1):53-60 Aug. 1992.
McCarthy et al. Molecular Microbiology 2:455-65 1988.
Verbon et al. Scand. J. Immunol. 36:371-84 (Mar. 1992).
Schauder et al. Gene 52(1):279-83 1987.
Andersen et al. Infection and Immunity 57(8):2481-88 1989.
Young et al. Infection and Immunity 54(1): 177-83 1986.
Deres et al. Nature 342:561-564 1989.
Wiker et al. Journal of General Microbiology 137(4): 875-84 Apr. 1991.
Sambrook, J. Molecular Cloning, A Laboratory Manual, 2nd Edition pp. 17.37-17.41 1989.
Singh Mahavir
Timmis Kenneth Nigel
Gesellschaft fuer Biotechnologische Forschung mbH (GBF)
Minnifield Nita
LandOfFree
Hybrid plasmid for 38 kDa antigen of M. tuberculosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid plasmid for 38 kDa antigen of M. tuberculosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid plasmid for 38 kDa antigen of M. tuberculosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1246757